Second- and third-generation ALK inhibitors for non-small cell lung cancer

被引：0
作者：
Jingjing Wu
John Savooji
Delong Liu
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[2] Westchester Medical Center and New York Medical College,Department of Medicine
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Brain Metastasis; Pemetrexed; Anaplastic Lymphoma Kinase; Anaplastic Large Cell Lymphoma; Crizotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
引用
收藏
相关论文
共 50 条
  • [31] Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
    Singh, Abhay
    Chen, Hongbin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6615 - 6628
  • [32] An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer
    Ai, Xinghao
    Shen, Shengping
    Shen, Lan
    Lu, Shun
    BIOCHIMIE, 2015, 112 : 111 - 120
  • [33] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [34] Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
    Laird Cameron
    Benjamin Solomon
    Drugs, 2015, 75 : 1059 - 1070
  • [35] Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
    Kitadai, Rui
    Okuma, Yusuke
    Kashima, Jumpei
    CASE REPORTS IN ONCOLOGY, 2019, 12 (01): : 171 - 177
  • [36] ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
    Elliott, Jesse
    Bai, Zemin
    Hsieh, Shu-Ching
    Kelly, Shannon E.
    Chen, Li
    Skidmore, Becky
    Yousef, Said
    Zheng, Carine
    Stewart, David J.
    Wells, George A.
    PLOS ONE, 2020, 15 (02):
  • [37] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [38] New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer
    Cameron, Laird
    Solomon, Benjamin
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (10)
  • [39] Characteristics and outcomes of ALK plus non-small cell lung cancer patients in Korea
    Lim, Sung Hee
    Yoh, Kyung Ah
    Lee, Jong Seok
    Ahn, Myung-ju
    Kim, Yu Jung
    Kim, Se Hyun
    Zhang, Jie
    Patel, Dony
    Swallow, Elyse
    Kageleiry, Andrew
    Galebach, Philip
    Lee, Dongyeol
    Stein, Karen
    Degun, Ravi
    Park, Keunchil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E239 - E245
  • [40] EML4-ALK fusion gene in non-small cell lung cancer
    Lei, Yu
    Lei, Yan
    Shi, Xiang
    Wang, Jingjing
    ONCOLOGY LETTERS, 2022, 24 (02)
12345